The tumor suppressor p53 is important for inhibiting the development of breast carcinomas. However, little is known about the effects of increased p53 activity on mammary gland development. Therefore, the effect of p53 dosage on mammary gland development was examined by utilizing the p53+/m mouse, a p53 mutant which exhibits increased wild-type p53 activity, increased tumor resistance, a shortened longevity, and a variety of accelerated aging phenotypes. Here we report that p53+/m virgin mice exhibit a defect in mammary gland ductal morphogenesis. Transplants of mammary epithelium into p53+/m recipient mice demonstrate decreased outgrowth of wild-type and p53+/m donor epithelium, suggesting systemic or stromal alterations in the p53+/m mouse. Supporting these data, p53+/m mice display decreased levels of serum IGF-1 and reduced IGF-1 signaling in virgin glands. The induction of pregnancy or treatment of p53+/m mice with estrogen, progesterone, estrogen and progesterone in combination, or IGF-1 stimulates ductal outgrowth, rescuing the p53+/m mammary phenotype. Serial mammary epithelium transplants demonstrate that p53+/m epithelium exhibits decreased transplant capabilities, suggesting early stem cell exhaustion. These data indicate that appropriate levels of p53 activity are important in regulating mammary gland ductal morphogenesis, in part through regulation of the IGF-1 pathway.
Introduction
In response to cellular stress, the tumor suppressor p53 plays an important role in maintaining genome integrity and inhibiting both cancer formation and progression by regulating the expression of genes responsible for mediating DNA repair, cell cycle arrest, apoptosis, and senescence (Bunz et al., 1998; Chao et al., 2000; Vogelstein et al., 2000) . Dysfunctional p53 signaling pathways or p53 mutations are present in over 80% of all human cancers, including breast cancer (Lozano and Elledge, 2000) . Proper function and regulation of p53 are important to prevent the development of human breast cancer, as mutations in p53 are found in 30-40% of spontaneous breast carcinomas and female Li-Fraumeni syndrome patients who carry a germline mutation in one p53 allele have an increased incidence of earlyonset breast cancer (Akashi and Koeffler, 1998; Coles et al., 1992; Moll et al., 1992) . Further work to understand the role of p53 in mammary gland development may provide insight into mechanisms that regulate malignant transformation as well as normal mammary epithelial cell growth.
The loss of p53 has been reported to have little effect on mammary gland development, as p53 null mammary glands were initially shown to be morphologically and functionally comparable to wild-type glands (Donehower et al., 1992; Jacks et al., 1994; Kuperwasser et al., 2000; Purdie et al., 1994) . However, loss of p53 in a BALB/c background causes a tran-sient delay in involution, indicating that p53 is expressed by the mammary epithelium during early involution, where it mediates apoptosis (Jerry et al., 1998) . In the quiescent virgin gland, p53 mRNA levels are high in the mammary epithelium; however, the virgin gland exhibits a decreased p53 response to DNA damage, characterized by cytoplasmic sequestration of p53 (Kuperwasser et al., 2000; Minter et al., 2002) . p53 activation is highest during early and mid-pregnancy, correlating with an increase in proliferation and steroid hormones (Becker et al., 2005; Minter et al., 2002) . Interestingly, treatment with pregnancy-associated hormones allows nuclear accumulation of p53 following irradiation in virgin glands (Kuperwasser et al., 2000) . Limited hormonal exposure of the mammary gland during postpubertal development, through pregnancy or hormonal treatment, has a protective effect against breast cancer in humans and rodents, which is dependent on the presence of wild-type p53 (Medina and Kittrell, 2003) . These studies show that p53 activity is dependent upon hormonal status and varies throughout development.
Recent studies have identified the ability of truncated forms of p53 to enhance the activity of full-length wild-type p53, including a mouse model developed in our laboratory, the p53+/m mouse (Tyner et al., 2002) . The p53+/m mice express one wild-type p53 allele and a truncated C-terminal p53 mutant allele, referred to as the "m" allele, which consists of p53 exons 7-11, with an Arg to Trp mutation at codon 245 (Tyner et al., 2002) . p53+/m mice are highly resistant to tumors, yet display a reduction in median life span and exhibit a variety of accelerated aging phenotypes (Tyner et al., 2002) . The p53+/m mice also exhibit alterations in hematopoietic stem cell (HSC) number, proliferation, and engraftment capabilities with age, suggesting that altered p53 levels affect stem cell functionality Gatza et al., 2007) . In response to γ-irradiation, p53+/m tissues exhibit increased wild-type p53 protein levels, indicating that the m protein can stabilize wild-type p53 (Tyner et al., 2002; Moore et al., in press) . The m allele also increases the activity of wild-type p53, leading to increased transactivation of the p53 target gene p21 and increased resistance to oncogenic transformation in MEFs (Tyner et al., 2002) . Although the m protein is not a natural isoform of p53, it is similar to several naturally occurring p53 isoforms, p44 and Δ133p53 (Bourdon et al., 2005) . In addition, the similarities between the p53+/m and p44 mouse models indicate that the p53+/m mouse is biologically significant as a model of increased p53 activity (Maier et al., 2004; Tyner et al., 2002) .
Since p53 levels play an important role in protection against mammary carcinogenesis, we investigated the effect of increased p53 activity on mammary gland development and stem cell dynamics by utilizing the p53+/m mouse model. Mammary gland stem cells are necessary for mammary gland development and functionality, and alterations in stem cell proliferative capabilities may lead to defects in the gland Stingl et al., 2006; Woodward et al., 2005) . Additionally, IGF-1, which plays a critical role in mediating mammary gland development, has also been implicated in aging (Holzenberger et al., 2003) . p53 is known to transcriptionally repress expression of the IGF-1 receptor (IGF-1R) and transcriptionally upregulate IGF-1 signaling inhibitors IGF-BP3 and PTEN, demonstrating a direct role in p53-mediated regulation of the IGF-1 pathway (Buckbinder et al., 1995; Stambolic et al., 2001; Werner et al., 1996) . Recently, several mouse models with accelerated aging phenotypes have been shown to exhibit alterations in IGF-1 signaling (Maier et al., 2004; Niedernhofer et al., 2006; Shukla et al., 2006) . Collectively, these studies suggest that the p53+/m mouse may exhibit altered IGF-1 signaling, which could affect mammary gland development.
Here we report that p53+/m virgin mice exhibit a defect in mammary gland ductal morphogenesis. Transplants of mammary epithelium into p53+/m recipient mice demonstrate a significant reduction of WT and p53+/m donor epithelium outgrowth, suggesting systemic or stromal alterations in p53+/m mice. In fact, p53+/m mice exhibit a decrease in serum IGF-1 levels and attenuated IGF-1 signaling in the virgin gland. The p53+/m mammary phenotype is rescued by induction of pregnancy, treatment with estrogen, progesterone, estrogen, and progesterone in combination, or LR3-IGF-1.
Collectively, these data demonstrate that alterations in p53 activity can have a profound effect in the regulation of mammary gland development.
Materials and Methods

Mice
The mice used in this study were previously reported by our laboratory (Donehower et al., 1992; Tyner et al., 2002) , except the TTR-IGF-1 mice (Liao et al., 2006) . p53 wild-type (WT) and p53+/m mice backcrossed seven generations into C57BL/6 and p53+/− mice backcrossed 12 generations into C57BL/6 were used for all experiments. The WT and p53+/m mice were generated by crossing WT mice to p53+/m mice and were genotyped by PCR as previously described . p53+/− mice were produced by heterozygous crossings and were genotyped by Southern Blot analysis as previously described (Donehower et al., 1992) . TTR-IGF-1 heterozygous mice were crossed to BC7-p53+/m mice to generate TTR-IGF-1/+;p53+/m mice and were genotyped by PCR as previously described Liao et al., 2006) . All mice were bred and maintained in a specific pathogen free animal facility at Baylor College of Medicine. The 3-week-old C57BL/6 female recipient mice used in the serial mammary epithelial transplantation experiments were purchased from the Baylor College of Medicine Transgenic Mouse Barrier Facility.
Whole mount preparation
Mammary gland tissue was isolated and whole mounts were prepared as previously described (Medina et al., 2002) . The number four inguinal mammary glands were harvested from WT, p53+/−, and p53+/m mice at 8 week virgin, 12 week virgin, 24 week virgin, mid-pregnancy (day 12), and D10 involution (10 days post weaning) and fixed in 10% neutral buffered formalin for at least 24 h. Whole mounts were examined for ductal outgrowth under a dissecting microscope (Olympus SZX12).
In vivo BrdU incorporation
Two hours prior to sacrifice, mice were treated with 7 mg/ml bromodeoxyuridine (BrdU) cell proliferation reagent (Sigma Aldrich, St. Louis, MO, USA) at 0.01 ml/gm of body weight. The number four inguinal mammary glands were harvested from WT, p53+/−, and p53+/m mice at 8 week virgin, 12 week virgin, mid-pregnancy (day 12), and D10 involution and fixed in 4% paraformaldehyde for 2 h followed by 70% ethanol. Fixed tissues were paraffin-embedded and sectioned. Immunostaining for BrdU incorporation was performed using the BrdU In-Situ Detection Kit (BD Pharmingen, San Diego, CA, USA). For each sample, 500 ductal epithelial cells were counted over multiple fields and scored as positive or negative for BrdU incorporation. The BrdU labeling index was determined by calculating the average of the percent BrdU positive cells from three separate glands.
TUNEL assay
The number four mammary glands were harvested from WT, p53+/−, and p53+/m mice at 8 week virgin, 12 week virgin, mid-pregnancy (day 12), and D10 involution and fixed in 4% paraformaldehyde for 2 h followed by 70% ethanol. Fixed tissues were paraffin embedded and sectioned. Immunostaining for apoptosis was performed using the In Situ Apoptosis Detection Kit (Trevigen, Helgerman, CT, USA). For each sample, 500 cells were counted over multiple fields and scored as TUNEL positive or negative. The percent apoptosis was determined by calculating the average of the percent TUNEL positive cells from three separate glands.
Serial mammary epithelial transplants
Serial mammary transplants were performed as previously described (Medina et al., 2002) . Briefly, the number four inguinal glands of five 3-week-old female WT C57BL/6 recipients were cleared by removal of the duct containing fat pad below the primary lymph node and proximal to the nipple. A 1 mm 2 piece of tissue from the number four mammary gland of an 8-week-old female WT, p53+/−, or p53+/m donor mouse was transplanted into the cleared glands of each of the five WT C57BL/6 recipients. Eight weeks post transplant, the outgrowths were retransplanted into five WT recipients and the glands were harvested, fixed in 4% paraformaldehyde for 2 h, transferred to 70% ethanol, and then paraffin embedded or examined by whole mount. Serial transplants were continued until the outgrowths failed to fill 10% of the mammary fat pad.
Mammary epithelium transplants into p53+/m recipients
The mammary glands of 3-week-old WT or p53+/m recipients were cleared as previously described. Mammary epithelium from an 8-week WT donor was transplanted into the left gland, while tissue from an 8-week p53+/m donor was transplanted into the right mammary gland of each recipient mouse. Transplants were harvested 4 weeks post transplant and whole mounted as previously described. Examination of outgrowth was performed by blinded assessment of whole mounts.
Hormone treatment
Ten to 12 week WT, p53+/−, and p53+/m virgin mice were subcutaneously implanted in the sub-scapular region with Silastic brand capsules (Dow Corning, Midland, MI, USA) containing either 50 μg estrogen (Sigma Aldrich, St. Louis, MO, USA), 20 mg progesterone (Sigma Aldrich, St. Louis, MO, USA), or 50 μg estrogen and 20 mg progesterone. The number four inguinal mammary glands were removed at day zero (untreated) and day 14, fixed in 10% neutral buffered formalin, and analyzed for ductal outgrowth by whole mount analysis.
IGF-1 serum analysis
Blood was collected retro-orbitally from anesthetized (Isoflurane) 8 week WT, p53+/−, and p53+/m virgin mice using heparinized capillary tubes (Fisher Scientific, Pittsburgh, PA, USA) and serum was collected by centrifugation. IGF-1 serum levels were analyzed by an enzyme-immuno-assay kit (Immunodiagnostic Systems, Ltd., Boldon Business Park, Bolden, Tyne and Wear, NE, USA) according to the manufacturer's instructions.
Western blotting
Mammary gland extracts were prepared from 8 week virgin mice or 5 week WT and p53+/m virgin mice untreated or treated once with 100 μl of 0.25 μg/μl LR3-IGF-1 recombinant analog (Sigma Aldrich, St. Louis, MO, USA) in 0.9% saline + 10 mg/ml BSA. Tissue was harvested 1 h post treatment. Mammary gland extracts were prepared by pulverizing snap-frozen tissue followed by lysis in RIPA buffer (Pierce, Rockford, IL, USA) plus a protease inhibitor cocktail (Roche, Applied Science, Mannheim, Germany) and phosphatase inhibitors (Pierce, Rockford, IL, USA), and cleared by centrifugation. Protein concentrations were determined using the BCA protein quantification assay (Pierce, Rockford, IL, USA). Extracts were electrophoresed on a 3-8% Tris-Acetate gel (Invitrogen, Carlsbad, CA, USA) or 4-12% Bis-Tris gel (Invitrogen, Carlsbad, CA, USA) and transferred to PVDF membrane (Invitrogen, Carlsbad, CA, USA). Membranes were blocked in 5% Milk-TBS-0.1% Tween followed by incubation with IRS-1 (Upstate Lake Placid, NY, USA), AKT (Cell Signaling, Danvers, MA, USA), pAKT (Ser473) (Cell Signaling, Danvers, MA, USA), IGF-1R (Santa Cruz Biotechnology, Santa Cruz, CA, USA), pIGF-1R (Tyr1135/ 1136) (Cell Signaling, Danvers, MA, USA), p21 (F-5) (Santa Cruz Biotechnology, Santa Cruz, CA, USA), p53 (R19) (Santa Cruz Biotechnology, Santa Cruz, CA, USA), and Actin (Lab Vision, Freemont, CA, USA). Peroxidase-conjugated bovine anti-rabbit (Santa Cruz Biotech, Santa Cruz, CA, USA) and anti-mouse secondary antibodies (Santa Cruz Biotech, Santa Cruz, CA, USA) were used at 1:2000 and signal was detected with Supersignal West Pico Solutions (Pierce, Rockford IL, USA). Membranes were stripped and re-probed whenever possible. Protein levels were determined by immunoblot analysis followed by densitometric analysis (GE Molecular Dynamics Personal Densitometer SI) utilizing ImageQuaNT software (GE Molecular Dynamics).
Treatment of mice with LR3-IGF-1
Six-week WT, p53+/−, and p53+/m virgin mice were intraperitoneally (IP) injected twice daily with 100 μl of 0.25 μg/μl LR3-IGF-1 recombinant analog (Sigma Aldrich, St. Louis, MO, USA) in 0.9% saline + 10 mg/ml BSA for 5 days. Control mice were IP injected twice daily with sterile 0.9% saline + 10 mg/ ml BSA. Mammary glands were harvested, fixed in 10% neutral buffered formalin, and whole mounted as previously described. Examination of ductal outgrowth was performed by assessment of whole mounts using a dissecting microscope (Olympus SZX12).
Analysis of IGF-1 mRNA levels
Total RNA was extracted from 12 week virgin WT, p53+/−, and p53+/m mammary glands using the RNeasy Lipid Tissue Mini Kit per the manufacturer's instructions (Qiagen, Valencia, CA, USA). One microgram of RNA was reverse transcribed using the SuperScript First Strand Synthesis System for RT PCR (Invitrogen, Carlsbad, CA, USA). Each PCR reaction contained 1 μg of cDNA along with IGF-1 primers IGF-1F 5′ GGA CCA GAG ACC CTT TGC GGG G 3′ and IGF-1R 5′ AAC AGA ACT TAG GAC GAG GG 3′ or β-actinF 5′ AAC AGA ACT TAG GAC GAG GG 3′ and β-actinR 5′ GGA AAC CAG GTT GTC AGT C 3′ and was run for 35 cycles. These primers generate a 267 bp IGF-1 product and a 209 bp β-actin product, respectively. IGF-1 expression was normalized to β-actin levels using KODAK Digital Science 1D Software.
Results
p53+/m mice exhibit delayed ductal morphogenesis
Mammary gland morphology was examined during developmental stages 8, 12, and 24 week virgin, mid-pregnancy (day 12), and involution (day 10) in WT, p53+/−, and p53+/m mice by whole mount analysis. Consistent with previous reports, p53+/− mammary glands were comparable to wild-type and no phenotypic alterations were observed at any developmental stages (data not shown) (Donehower et al., 1992; Jacks et al., 1994; Purdie et al., 1994) . In contrast, mammary glands from 8 week old p53+/m virgin mice show reduced ductal outgrowth, with minimal ductal growth past the primary lymph node (Fig.  1A) . To confirm this delay in ductal morphogenesis, we examined p53+/m virgin mice at 12 and 24 weeks of age and found that these mice also exhibit decreased ductal outgrowth (Fig. 1A) . Despite decreased ductal outgrowth, the limited number of ducts in the p53+/m glands exhibit normal gross and cellular morphology when examined by whole mount analysis and by hematoxylin and eosin (H and E) staining (data not shown). Surprisingly, by mid-pregnancy (day 12), the glands of p53+/m mice were comparable to those of both WT and p53+/− mice, demonstrating ductal outgrowth encompassing the entire fat pad as well as normal formation of alveolar buds (Fig. 1B) . No morphological differences in involution (day 10) were noted between WT, p53+/−, and p53+/m glands (Fig. 1C) . Furthermore, it was observed that female p53+/m mice were capable of nursing their pups and supporting them until weaning, suggesting that p53+/m mammary glands are functionally analogous to wildtype glands post-partum. This suggests that the pregnancymediated increase in steroid hormones may be required to induce ductal outgrowth in the p53+/m mammary gland.
Rates of cell proliferation and apoptosis during development
The p53+/m mice were previously shown to exhibit increased levels of p53 protein in response to irradiation in the kidney (Tyner et al., 2002) . Although p53 protein levels were not significantly increased in the mammary glands of p53+/m virgin mice, these glands exhibit an increase in p21 levels in response to irradiation, indicative of an increase in p53 activity ( Supplementary Fig. 1 ). The increased p53 activity in the p53+/m mouse suggests that the decreased ductal outgrowth observed in these mice could be due to alterations in proliferation and/or apoptosis, which are important during ductal morphogenesis, successive cycles of pregnancy, and critical during involution (Richert et al., 2000) . An in vivo BrdU proliferation assay was performed to determine if levels of proliferation were altered in the p53+/m mammary gland. Proliferation was examined in WT, p53+/−, and p53+/m mice at developmental stages 8 and 12 week virgin, mid-pregnancy (day 12), and D10 involution. No proliferation was observed in the limited number of ductal epithelial cells found in the 8 and 12 week p53+/m virgin glands; however, by mid-pregnancy (day 12) and during involution, the p53+/m glands exhibited rates of cell proliferation comparable to both WT and p53+/− glands (Figs. 2A, B) . These results further suggest that pregnancy is required to induce epithelial cell proliferation and ductal outgrowth in the p53+/m gland. A TUNEL assay was performed to examine levels of apoptosis in WT, p53+/−, and p53+/m mice during various developmental stages. Consistent with our previous results, limited numbers of ductal epithelial cells were observed in the p53+/m 8 and 12 week virgin glands. Virgin glands showed comparable low levels of apoptosis across all genotypes and no significant increase in apoptosis was detected in these glands by TUNEL assay (Figs. 2C, D) . Moreover, we did not observe alterations in apoptotic levels between genotypes at midpregnancy (day 12) or D10 involution and no differences in morphology were seen at D10 involution (Figs. 1D, 2C, D ). These data demonstrate that the m allele does not increase apoptosis in the mammary gland, so apoptosis does not play a role in the ductal defect seen in the p53+/m virgin gland.
Mammary epithelial transplants into p53+/m recipients exhibit reduced ductal outgrowth
The delayed ductal outgrowth observed in the virgin p53+/m gland suggests that mammary gland stem proliferation and/or Fig. 3 . Mammary epithelium transplants demonstrate that p53 dosage alters the systemic environment. (A) Representative whole mounts of WT and p53+/m serial mammary epithelial transplants into wild-type recipient mice (transplant number one) demonstrate complete ductal outgrowth in p53+/m transplants. (B) Representative whole mounts of WT and p53+/m mammary epithelium transplants into p53+/m recipient mice 4 weeks post transplant demonstrate reduced ductal outgrowth of both WT and p53+/m transplants into p53+/m recipient mice. Each recipient mouse was transplanted with WT mammary epithelium in the left mammary gland and p53+/m mammary epithelium in the right gland. All images are shown at 3.5× magnification. differentiation may be inhibited by increased p53 activity (Fig. 1) . Therefore, we compared the replicative life span of WT, p53+/−, and p53+/m mammary gland stem cells in vivo by performing serial mammary epithelium transplants into wildtype recipient mice. The p53+/m transplants exhibited a slightly reduced regenerative capacity compared to their WT counterparts, suggesting that cell autonomous effects of augmented p53 activity in the p53+/m mammary stem cells may have a marginal effect on stem cell regeneration (Supplementary Table  1 ). Interestingly, p53+/m transplants were capable of growing to fill the entire mammary fat pad by 8 weeks post transplant, suggesting a systemic effect on mammary gland development in the p53+/m mice (Fig. 3A) .
The complete ductal outgrowth observed in the serial transplantation of p53+/m epithelium into WT recipients, in contrast to the limited ductal outgrowth seen in virgin p53+/m glands, suggests that systemic or stromal alterations in the p53+/m mice may play a major role in the p53+/m mammary defect. The mammary stroma has been reported to play an important role in regulating development and ductal morphogenesis in the mammary gland (Walden et al., 1998) . Proliferation signals mediated through epithelial-stromal crosstalk such as IGF-1, estrogen, and progesterone are critical for normal development to occur (Ruan and Kleinberg, 1999; Ruan et al., 2005) . To determine if systemic or stromal alterations were affecting ductal outgrowth in the p53+/m mice, mammary epithelial transplants were performed with p53+/m recipient mice. Mammary glands from WT or p53+/m virgin recipient mice were cleared and transplanted with 8 week virgin WT donor epithelium in the left gland and 8 week virgin p53+/m donor epithelium in the right gland to allow for a comparison of outgrowth. Whole mount analysis of the transplanted glands revealed that the majority of WT and p53+/m transplants into WT recipient mice showed robust ductal outgrowth, with all outgrowth filling greater than 50% of the fat pad by 4 weeks post transplant (Fig. 3B, Table 1 ). However, it was noted that fewer p53+/m transplants demonstrated outgrowth compared to WT transplants (Table 1) . Interestingly, transplantation of either WT or p53+/m mammary epithelium into p53+/m recipient mice exhibited significantly reduced ductal outgrowth, with a mean percentage of fat pad filled of less than 20% in the majority of WT transplants and only 6% ductal outgrowth in the p53+/m transplants (Fig. 3B, Table 1 ). In addition, fewer WT and p53+/m transplants into p53+/m recipients demonstrated outgrowth (Table 1 ). These data suggest that the systemic increase in p53 activity and/or other systemic alterations in the p53+/m mice contribute to the developmental delay observed in the p53+/m mammary gland.
Steroid hormone treatment of p53+/m mice rescues mammary gland development
Examination of p53+/m whole mounts during development revealed that by mid-pregnancy (day 12), the p53+/m mammary gland exhibited complete ductal outgrowth with normal development of alveolar structures comparable to WT glands (Fig. 1B) . These results suggest that increased levels of steroid hormones during pregnancy may be required to allow ductal outgrowth in the presence of increased p53 levels. To determine whether hormonal treatment is capable of stimulating mammary gland development in virgin p53+/m mice, mice were treated with estrogen, progesterone, or a combination of estrogen and progesterone for 14 days. Whole mount examination of mammary glands demonstrates that treatment with estrogen alone, progesterone alone, or estrogen and progesterone in combination rescues the ductal defect in virgin p53+/m mice, stimulating ductal outgrowth past the primary lymph node (Fig.  4) . These data confirm that alterations in hormone levels induced by pregnancy are capable of stimulating ductal outgrowth in the p53+/m mice. p53+/m mice exhibit decreased levels of serum IGF-1 and attenuated IGF-1 signaling
The decreased outgrowth observed in mammary epithelium transplants into p53+/m recipient mice, in addition to the stimulation of ductal outgrowth by hormonal treatment, suggests that the increased p53 activity in the p53+/m mice leads to alterations in stromal or systemic signaling which may play a role in the decreased ductal growth. Estrogen and progesterone are both known to enhance IGF-1 activity during ductal morphogenesis (Ruan et al., 2005) . IGF-1, which is produced primarily in the stroma and mediates the proliferation signals of growth hormone in an autocrine fashion through stroma-epithelial crosstalk, is known to play a critical role in ductal morphogenesis (Ruan and Kleinberg, 1999) . In addition, serum IGF-1 may affect the mammary gland in an endocrine manner (Liu and LeRoith, 1999; Ruan and Kleinberg, 1999) . Interestingly, IGF-1 null mice exhibit impaired mammary gland development characterized by decreased numbers of terminal end buds and ducts as well as a decrease in the percentage of fat pad occupied by ductal outgrowth (Ruan and Kleinberg, 1999) . Since these phenotypes are comparable to those seen in the p53+/m mammary gland and p53 itself has been shown to play an integral role in regulating IGF-1 signaling through transcrip- tional repression of the IGF-1R (Werner et al., 1996) , levels of IGF-1 were examined in the p53+/m mouse. Serum levels of IGF-1 were found to be significantly decreased (34%) in 8 week virgin p53+/m mice when compared to WT mice of the same age (Fig. 5A) . While the decrease in circulating IGF-1 levels may contribute to the p53+/m mammary phenotype, it has been reported that paracrine levels of IGF-1 may play a more important role in mammary ductal morphogenesis than circulating levels of IGF-1 (Richards et al., 2004) . Therefore, RT-PCR was performed to examine in situ levels of IGF-1 mRNA in the mammary gland and levels of IGF-1 signaling proteins were examined by Western blot analysis. p53+/m virgin glands exhibit reduced levels of insulin-receptor substrate 1 (IRS-1), IGF-1R, pIGF-R, AKT, and pAKT proteins, demonstrating reduced IGF-1 signaling (Fig. 5B ), although no difference was observed in levels of IGF-1 mRNA in p53+/m virgin mammary glands when compared to WT glands ( Supplementary Fig. 2 ). These data suggest that decreased IGF-1 serum levels lead to decreased IGF-1 signaling in the p53+/m virgin mammary gland which may contribute to the mammary phenotype.
Increased IGF-1 serum levels rescue mammary gland development in p53+/m mice To determine if the decrease in serum IGF-1 contributes to the decreased ductal outgrowth, p53+/m mice were treated twice daily with LR3-IGF-1 for 5 days. Examination of whole mounts following LR3-IGF-1 treatment demonstrated a rescue of ductal morphogenesis, characterized by increased ductal outgrowth past the primary lymph node, with a significant increase in the mean percentage of fat pad filled by ductal outgrowth (Fig. 5C, Supplementary Fig. 3 ). LR3-IGF-1 treatment of p53+/m mice also restored levels of IGF-1 signaling, with levels of IRS-1, IGF-1R, pIGF-R, pAKT, and AKT proteins comparable to wild-type post treatment (Fig. 5B) .
Additionally, p53+/m mice were crossed to TTR-IGF-1/+ mice, which contain three copies of an IGF-1 transgene under the transthyretin promoter, which allows for liver specific overexpression of IGF-1, resulting in a 50-60% increase in serum IGF-1 levels (Liao et al., 2006) . To determine if the increased serum IGF-1 levels in the TTR-IGF-1/+ mice could rescue the mammary phenotype of the p53+/m mice, 8 week virgin glands from TTR-IGF-1/+;p53+/m mice were examined by whole mount. TTR-IGF-1/+;p53+/m virgin glands exhibit an increase in ductal outgrowth past the primary lymph node (Fig. 5D) , suggesting that the increased serum IGF-1 levels due to the presence of the TTR-IGF-1 transgenes is sufficient to rescue the p53+/m mammary gland defect. These data confirm that decreased levels of serum IGF-1 and decreased IGF-1 signaling contribute to the p53+/m mammary phenotype.
Discussion
The data reported here demonstrate that the increased wildtype p53 activity observed in the p53+/m mouse leads to a defect in mammary gland ductal morphogenesis, which is characterized by minimal ductal outgrowth beyond the primary lymph node in virgin mice. Previous studies have reported that p53 typically remains cytoplasmically sequestered in virgin glands, demonstrating that p53 activity is tightly regulated in the quiescent virgin gland (Kuperwasser et al., 2000; Minter et al., 2002) . We have previously shown that the m allele increases both p53 stability and activity (Tyner et al., 2002; Moore et al., in press ). Additionally, the m allele drives nuclear localization of p53 even in the absence of stress, which may contribute to the increased p53 activity observed in the presence of the m allele (Moore et al., in press) . Although no significant increase in p53 protein levels was observed in the p53+/m virgin mammary gland, there is an increase in levels of p21 in response to irradiation, suggesting an increase in p53 activity in the p53+/m mammary gland (Supplementary Fig. 1 ). An increase in p53 activity could result in altered apoptotic levels. However, no increase in apoptosis was observed at any developmental stage, demonstrating that apoptosis does not play a role in the mammary phenotype of the p53+/m mouse. Increases in p53 activity in other tissues in the p53+/m mice, as previously observed in the kidney (Tyner et al., 2002) , could cause systemic effects that alter mammary gland development, such as the observed decrease in serum IGF-1 levels. In fact, preliminary data suggest that there is a reduced ratio of IGF-1/ IGFBP-3 mRNA levels in p53+/m liver (M. Pollak, unpublished data).
The ability of p53+/m serial mammary epithelial transplants to exhibit complete ductal outgrowth in a WT fat pad suggested that systemic or stromal alterations in the p53+/m mice, such as loss of IGF-1 signaling, contribute to the phenotype. In fact, p53+/m mice exhibit a reduction in IGF-1 serum levels that may contribute to the decreased proliferation observed in the p53+/m virgin gland. This suggests that p53 may be able to directly or indirectly regulate IGF-1 levels, although the mechanism remains unknown at this time. Interestingly, two progeroid mouse models, the DNA repair deficient XPF-ERCC1−/− mouse and the Csb m/m /Xpa −/− mouse, exhibit a reduced life span and chronic genotoxic stress which leads to suppression of the GH/IGF-1 somatotroph axis van der Pluijm et al., 2006) . It is possible that the increased p53 activity in the p53+/m mice may potentially replicate some aspects of the chronic genotoxic stress observed in these mice, as p53 is directly activated by genotoxic stress. The increased p53 activity in the p53+/m mice could induce a chronic augmented stress response, which may lead to the downregulation of the IGF-1 somatotrophic axis.
It was previously reported that paracrine levels of IGF-1 may play a more important role in mammary ductal morphogenesis than circulating levels of IGF-1 (Richards et al., 2004) . However, the rescue of the p53+/m mammary phenotype by systemic treatment with LR3-IGF-1 and by crossing to the TTR-IGF-1/+ mice suggests that serum levels of IGF-1 significantly contribute to mammary gland development. Although RT-PCR analysis showed no alterations in IGF-1 mRNA levels in the p53+/m mammary gland itself, these glands exhibit a decrease in levels of IGF-1 signaling proteins, including the IGF-1R, a p53 target gene. p53 is known to transcriptionally repress expression of the IGF-1R and transcriptionally activate expression of IGF-1 signaling inhibitors IGF-BP3 and PTEN, demonstrating a direct role in p53-mediated regulation of the IGF-1 pathway (Buckbinder et al., 1995; Stambolic et al., 2001; Werner et al., 1996) . In fact, disruption of the IGF-1R gene has been shown to reduce levels of proliferation in terminal end buds (Bonnette and Hadsell, 2001) . These data suggest that the increased p53 activity in the p53+/m mouse attenuates IGF-1 signaling.
Strikingly, the p53+/m mice are also highly tumor resistant, which may be due in part to reduced levels of circulating IGF-1, as an increase in IGF-1 and IGF-1R levels has been shown to correlate with an increased risk of tumor development (Hankinson et al., 1998) . In contrast to the p53+/m model, some of the premature aging mouse models which have been shown to exhibit increased IGF-1 levels also display increased incidence of tumorigenesis (Shukla et al., 2006; Xu et al., 2001) .
Surprisingly, we saw a complete rescue of the p53+/m mammary gland phenotype with the induction of pregnancy. This rescue may be due to increased levels of estrogen and progesterone which are known to cause secondary changes in growth factor expression (Sternlicht et al., 2006) . Interestingly, there is evidence that pregnancy can upregulate IGF signaling (Bonnette and Hadsell, 2001) , suggesting that pregnancy may compensate for the reduction in circulating IGF-1 levels and decreased IGF-1 signaling observed in the p53+/m mice. In fact, both progesterone and estrogen have been shown to synergize with and enhance IGF-1-mediated ductal morphogenesis (Ruan et al., 2005) . Supporting this, our data demonstrate that treatment with estrogen, progesterone, estrogen plus progesterone, or LR3-IGF-1 stimulates ductal outgrowth in the p53+/m gland. While we cannot rule out a p53-mediated reduction in estrogen or progesterone, we observed no alterations in fecundity or fertility in p53+/m mice, suggesting that alterations in estrogen and/or progesterone do not contribute to the mammary phenotypes. These data suggest that p53-mediated regulation of the IGF-1 signaling pathway may contribute to mammary gland development and support a model in which pregnancy-induced proliferation signals compensate for the increased p53 activity in the p53+/m mouse by stimulating or synergizing with IGF-1 signaling.
The decreased ductal outgrowth observed in transplantation of wild-type and p53+/m mammary epithelium into p53+/m recipients suggests that serum and/or stromal factors may also play a major role in the extrinsic regulation of mammary stem cell proliferation (Fig. 3B, Table 1 ). One of these extrinsic factors is likely to be IGF-1, as there is growing evidence that multiple stem cell types are functionally stimulated by IGF-1 (Bendall et al., 2007; Musaro et al., 2004) . Intrinsic cell autonomous effects of enhanced p53 in the mammary gland stem cells may have only a minor role, as p53+/m mammary gland stem cells exhibited a marginal reduction in serial transplantation capacity compared to their WT counterparts (Supplementary Table 1 ). However, additional studies will be required to further clarify the role of p53 in regulation of the mammary gland stem cell.
The data presented here suggest that increased p53 activity can dramatically affect mammary gland development, in part through regulation of IGF-1 signaling. The increased p53 activity present in p53+/m mice during mammary gland ductal morphogenesis contributes to decreased proliferation in virgin glands, decreased levels of serum IGF-1, and decreased IGF-1 signaling in p53+/m virgin glands. However, other effects of enhanced p53 on estrogen and progesterone receptor signaling could also be playing an important role in this model. Collectively it is believed that these effects of increased p53 activity lead to the decreased ductal outgrowth observed in the p53+/m virgin glands. Our work solidifies the link between p53 and hormonal regulation, demonstrating that hormonal stimulation is able to overcome the proliferative block induced by increased p53 activity. These data suggest that the regulation of p53 activity is important for mammary gland development.
However, further work is needed to fully elucidate the effects of altering p53 levels.
